Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Citi
UBS
US Army
Chubb
QuintilesIMS
Farmers Insurance
Queensland Health
US Department of Justice
Cipla

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202726

« Back to Dashboard

NDA 202726 describes GEMFIBROZIL, which is a drug marketed by Mylan, Purepac Pharm, Apotex, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Caribe Holdings, Chartwell Molecules, Hikma Pharms, Impax Pharms, Invagen Pharms, Northstar Hlthcare, Sun Pharm Inds Inc, Teva, Watson Labs, and Yaopharma Co Ltd, and is included in eighteen NDAs. It is available from fifty-two suppliers. Additional details are available on the GEMFIBROZIL profile page.

The generic ingredient in GEMFIBROZIL is gemfibrozil. There are twenty drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the gemfibrozil profile page.
Summary for 202726
Tradename:GEMFIBROZIL
Applicant:Aurobindo Pharma Ltd
Ingredient:gemfibrozil
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 202726
Medical Subject Heading (MeSH) Categories for 202726
Suppliers and Packaging for NDA: 202726
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GEMFIBROZIL gemfibrozil TABLET;ORAL 202726 ANDA Citron Pharma LLC 57237-163 N 57237-163-60
GEMFIBROZIL gemfibrozil TABLET;ORAL 202726 ANDA Citron Pharma LLC 57237-163 N 57237-163-05

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength600MG
Approval Date:Sep 16, 2015TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Boehringer Ingelheim
Merck
Johnson and Johnson
Federal Trade Commission
Teva
Argus Health
Accenture
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot